Effectiveness of pazopanib and SBRT in metastatic renal cell carcinoma

被引：0
|
作者：
Cihan, Yasemin Benderli [1 ]
机构：
[1] Kayseri Educ & Res Hosp, Dept Radiat Oncol, Ataturk Blvd,Hastane St 78, TR-38010 Kayseri, Turkey
来源：
WORLD JOURNAL OF UROLOGY | 2018年 / 36卷 / 11期
关键词：
BODY RADIATION-THERAPY;
D O I：
10.1007/s00345-018-2323-6
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1797 / 1798
页数：2
相关论文
共 50 条
  • [41] Pazopanib for the treatment of renal cell carcinoma
    Welsh, Sarah J.
    Fife, Kate
    FUTURE ONCOLOGY, 2015, 11 (08) : 1169 - 1179
  • [42] Pazopanib In Advanced Renal Cell Carcinoma
    Sanford, Mark
    Keating, Gillian M.
    BIODRUGS, 2010, 24 (05) : 279 - 286
  • [43] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
    Ruiz-Morales, Jose Manuel
    Swierkowski, Marcin
    Wells, J. Connor
    Fraccon, Anna Paola
    Pasini, Felice
    Donskov, Frede
    Bjarnason, Georg A.
    Lee, Jae-Lyun
    Sim, Hao-Wen
    Sliwczynsk, Andrzej
    Ptak-Chmielewska, Aneta
    Teter, Zbigniew
    Beuselinck, Benoit
    Wood, Lori A.
    Yuasa, Takeshi
    Pezaro, Carmel
    Rini, Brian I.
    Szczylik, Cezary
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    EUROPEAN JOURNAL OF CANCER, 2016, 65 : 102 - 108
  • [44] A RARE CASE OF TUMOR LYSIS SYNDROME IN METASTATIC RENAL CELL CARCINOMA TREATED WITH PAZOPANIB
    Jain, Prachi
    Sanchez, Paola
    Ciftci, Farah
    Sullivan, Lauren
    ANTICANCER RESEARCH, 2018, 38 (12) : 6962 - 6963
  • [45] Pazopanib The Newest Tyrosine Kinase Inhibitor for the Treatment of Advanced or Metastatic Renal Cell Carcinoma
    Keisner, Sidney V.
    Shah, Sachin R.
    DRUGS, 2011, 71 (04) : 443 - 454
  • [46] Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma
    Roberto, Michela
    Bassanelli, Maria
    Iannicelli, Elsa
    Giacinti, Silvana
    D'Antonio, Chiara
    Aschelter, Anna Maria
    Marchetti, Paolo
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2015, 2015
  • [47] Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma
    Santoni, Matteo
    Conti, Alessandro
    Porta, Camillo
    Procopio, Giuseppe
    Sternberg, Cora N.
    Basso, Umberto
    De Giorgi, Ugo
    Bracarda, Sergio
    Rizzo, Mimma
    Ortega, Cinzia
    Massari, Francesco
    Iacovelli, Roberto
    Derosa, Lisa
    Masini, Cristina
    Milella, Michele
    Di Lorenzo, Giuseppe
    Atzori, Francesco
    Pagano, Maria
    Buti, Sebastiano
    De Vivo, Rocco
    Mosca, Alessandra
    Rossi, Marta
    Paglino, Chiara
    Verzoni, Elena
    Cerbone, Linda
    Muzzonigro, Giovanni
    Falconi, Massimo
    Montironi, Rodolfo
    Burattini, Luciano
    Santini, Daniele
    Cascinu, Stefano
    JOURNAL OF UROLOGY, 2015, 193 (01): : 41 - 47
  • [48] Starting with low dose pazopanib in the treatment of Japanese patients with metastatic renal cell carcinoma
    Akatsuka, J.
    Kimura, G.
    Shibayama, K.
    Sano, M.
    Endo, Y.
    Takeda, H.
    Hamasaki, T.
    Kondo, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience
    Lalani, Aly-Khan A.
    Li, Haocheng
    Heng, Daniel Y. C.
    Wood, Lori
    Kalirai, Austin
    Bjarnason, Georg A.
    Sim, Hao-Wen
    Kollmannsberger, Christian K.
    Kapoor, Anil
    Hotte, Sebastien J.
    Vanhuyse, Marie
    Czaykowski, Piotr
    Reaume, M. Neil
    Soulieres, Denis
    Venner, Peter
    North, Scott
    Basappa, Naveen S.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2017, 11 (3-4): : 112 - 117
  • [50] Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients
    Poprach, Alexandr
    Fiala, Ondrej
    Chloupkova, Renata
    Melichar, Bohuslav
    Lakomy, Radek
    Petrakova, Katarina
    Zemanova, Milada
    Kopeckova, Katerina
    Slaby, Ondrej
    Studentova, Hana
    Kopecky, Jindrich
    Kiss, Igor
    Finek, Jindrich
    Dusek, Ladislav
    Buchler, Tomas
    ANTICANCER RESEARCH, 2018, 38 (01) : 449 - 456
12345